[1] |
POLITANO S A, COLBERT G B, HAMIDUZZAMAN N. Nephrotic syndrome[J]. Primary Care, 2020, 47(4): 597-613. DOI: 10.1016/j.pop.2020.08.002.
doi: 10.1016/j.pop.2020.08.002
pmid: 33121631
|
[2] |
ENE-IORDACHE B, PERICO N, BIKBOV B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study[J]. The Lancet Global Health, 2016, 4(5): e307-e319. DOI: 10.1016/S2214-109X(16)00071-1.
doi: 10.1016/S2214-109X(16)00071-1
|
[3] |
ZHANG L X, WANG F, WANG L, et al. Prevalence of chronic kidney disease in China: A cross-sectional survey[J]. Lancet (London, England), 2012, 379(9818): 815-822. DOI: 10.1016/S0140-6736(12)60033-6.
doi: 10.1016/S0140-6736(12)60033-6
|
[4] |
BRAD H, ROVIN. Management and treatment of glomerular diseases (part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney International, 2019, 95(2): 281-295. DOI: 10.1016/j.kint.2018.11.008.
doi: S0085-2538(18)30811-1
pmid: 30665569
|
[5] |
RAVANI P, BERTELLI E, GILL S, et al. Clinical trials in minimal change disease[J]. Nephrology Dialysis Transplantation, 2017, 32(s1): i7-i13. DOI: 10.1093/ndt/gfw235.
doi: 10.1093/ndt/gfw235
|
[6] |
TULLUS K, WEBB H, BAGGA A. Management of steroid-resistant nephrotic syndrome in children and adolescents[J]. The Lancet Child & Adolescent Health, 2018, 2(12): 880-890. DOI: 10.1016/S2352-4642(18)30283-9.
doi: 10.1016/S2352-4642(18)30283-9
|
[7] |
CHEN Y Q, CHEN H Y, TANG Q Q, et al. Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines[J]. Frontiers in Pharmacology, 2022, 13: 968226. DOI: 10.3389/fphar.2022.968226.
doi: 10.3389/fphar.2022.968226
|
[8] |
ZENG H M, GUO X P, ZHOU F, et al. Quercetin alleviates ethanol-induced liver steatosis associated with improvement oflipophagy[J]. Food and Chemical Toxicology: an International Journal Published for the British Industrial Biological Research Association, 2019, 125: 21-28. DOI: 10.1016/j.fct.2018.12.028.
doi: 10.1016/j.fct.2018.12.028
|
[9] |
GENG L L, LIU Z P, WANG S, et al. Low-dose quercetin positively regulates mouse healthspan[J]. Protein & Cell, 2019, 10(10): 770-775. DOI: 10.1007/s13238-019-0646-8.
doi: 10.1007/s13238-019-0646-8
|
[10] |
REYES-FARIAS M, CARRASCO-POZO C. The anti-cancer effect of quercetin: Molecular implications in cancer metabolism[J]. International Journal of Molecular Sciences, 2019, 20(13): 3177. DOI: 10.3390/ijms20133177.
doi: 10.3390/ijms20133177
|
[11] |
WANG X W, TIAN R M, YANG Y Q, et al. Tripterygium glycoside fraction n2 ameliorates adriamycin-induced nephrotic syndrome in rats by suppressing apoptosis[J]. Journal of Ethnopharmacology, 2020, 257: 112789. DOI: 10.1016/j.jep.2020.112789.
doi: 10.1016/j.jep.2020.112789
|
[12] |
LEE V W S, HARRIS D C H. Adriamycin nephropathy: A model of focal segmentalglomerulosclerosis[J]. Nephrology (Carlton, Vic), 2011, 16(1): 30-38. DOI: 10.1111/j.1440-1797.2010.01383.x.
doi: 10.1111/j.1440-1797.2010.01383.x
|
[13] |
ROSENBERG A Z, KOPP J B. Focal segmentalglomerulosclerosis[J]. Clinical Journal of the American Society of Nephrology, 2017, 12(3): 502-517. DOI: 10.2215/cjn.05960616.
doi: 10.2215/cjn.05960616
|
[14] |
包玉龙, 杨瑞, 刘禾, 等. 阿霉素大鼠肾病综合征模型最佳剂量的筛选[J]. 动物医学进展, 2018, 39(5): 61-63. DOI: 10.16437/j.cnki.1007-5038.2018.05.011.
doi: 10.16437/j.cnki.1007-5038.2018.05.011
|
[15] |
WU J B, YE S F, LIANG C L, et al. Qi-Dan Fang amelioratesadriamycin-induced nephrotic syndrome rat model by enhancing renal function and inhibiting podocyte injury[J]. Journal of Ethnopharmacology, 2014, 151(3): 1124-1132. DOI: 10.1016/j.jep.2013.12.028.
doi: 10.1016/j.jep.2013.12.028
|
[16] |
唐桂毅, 温和, 王晶晶, 等. 阿霉素肾病大鼠模型的评价研究[J]. 药物评价研究, 2020, 43(1): 66-71. DOI: 10.7501/j.issn.1674-6376.2020.01.011.
doi: 10.7501/j.issn.1674-6376.2020.01.011
|
[17] |
DOWNIE M L, GALLIBOIS C, PAREKH R S, et al. Nephrotic syndrome in infants and children: Pathophysiology and management[J]. Paediatrics and International Child Health, 2017, 37(4): 248-258. DOI: 10.1080/20469047.2017.1374003.
doi: 10.1080/20469047.2017.1374003
pmid: 28914167
|
[18] |
PRASAD R B, GROOP L. Precision medicine in type 2 diabetes[J]. Journal of Internal Medicine, 2019, 285(1): 40-48. DOI: 10.1111/joim.12859.
doi: 10.1111/joim.12859
pmid: 30403316
|
[19] |
ZHONG J Y, YANG H C, FOGO A B. A perspective on chronic kidney disease progression[J]. American Journal of Physiology Renal Physiology, 2017, 312(3): F375-F384. DOI: 10.1152/ajprenal.00266.2016.
doi: 10.1152/ajprenal.00266.2016
|
[20] |
MARTIN C E, JONES N. Nephrin signaling in the podocyte: An updated view of signal regulation at the slit diaphragm and beyond[J]. Frontiers in Endocrinology, 2018, 9: 302. DOI: 10.3389/fendo.2018.00302.
doi: 10.3389/fendo.2018.00302
pmid: 29922234
|
[21] |
GREKA A, MUNDEL P. Cell biology and pathology ofpodocytes[J]. Annual Review of Physiology, 2012, 74: 299-323. DOI: 10.1146/annurev-physiol-020911-153238.
doi: 10.1146/annurev-physiol-020911-153238
|
[22] |
YU S M W, NISSAISORAKARN P, HUSAIN I, et al. Proteinuric kidney diseases: A podocyte's slit diaphragm and cytoskeleton approach[J]. Frontiers in Medicine, 2018, 5: 221. DOI: 10.3389/fmed.2018.00221.
doi: 10.3389/fmed.2018.00221
|